SCHEMBL4305259

SCHEMBL4305259

CNc1cc(Oc2ccc(NC(=O)Nc3cc(C(C)(C)C)nn3-c3ccc(CN4CCOCC4)cc3)cc2)ncn1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 11/20 0.61
MAPK13 O15264 5/20 0.61
MAPK12 P53778 3/20 0.61
MAPK11 Q15759 3/20 0.61
MAPK9 P45984 2/20 0.61
GSK3A P49840 4/20 0.52
SYK P43405 4/20 0.52
SRC P12931 4/20 0.52
KDR P35968 6/20 0.51
TNNI3K Q59H18 6/20 0.51
BRAF P15056 4/20 0.51
FLT3 P36888 2/20 0.51
STK25 O00506 1/20 0.51
CIT O14578 1/20 0.51
MAP2K7 O14733 1/20 0.51
IKBKB O14920 1/20 0.51
AURKA O14965 1/20 0.51
GAK O14976 1/20 0.51
CHUK O15111 1/20 0.51
MUSK O15146 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4302985 0.92 MAPK14 (0.64) MAPK14MAPK13MAPK12MAPK11MAPK9
SCHEMBL4306029 0.91 MAPK14 (0.62) MAPK14MAPK13MAPK12MAPK11MAPK9
SCHEMBL4306959 0.88 MAPK14 (0.56) MAPK14MAPK13MAPK12MAPK11MAPK9
SCHEMBL2435659 0.84 KDR (0.52) MAPK14MAPK13MAPK12MAPK11MAPK9
SCHEMBL13859626 0.84 KDR (0.67) MAPK14MAPK13MAPK12MAPK11KDR
SCHEMBL13852786 0.82 MAPK14 (0.65) MAPK14MAPK13MAPK12MAPK11MAPK9
SCHEMBL13296803 0.79 MAPK14 (0.78) MAPK14MAPK13MAPK12MAPK11MAPK9
SCHEMBL4303704 0.78 MAPK14 (0.57) MAPK14MAPK13MAPK12MAPK11MAPK9
SCHEMBL2439158 0.78 KDR (0.50) MAPK14MAPK13MAPK12MAPK11MAPK9
SCHEMBL1409878 0.78 MAPK13 (0.69) MAPK14MAPK13MAPK12MAPK11MAPK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090131437-A1 DISUBSTITUTED UREAS AS KINASE INHIBITORS CORIUM INTERNATIONAL, INC. (US) 2009-05-21 US claimed
EP-1838700-A2 DISUBSTITUTED UREAS AS KINASE INHIBITORS Novartis AG (CH) 2007-10-03 EP claimed
WO-2006072589-A2 DISUBSTITUTED UREAS AS KINASE INHIBITORS NOVARTIS AG (CH) 2006-07-13 WO claimed
US-20090131437-A1 DISUBSTITUTED UREAS AS KINASE INHIBITORS CORIUM INTERNATIONAL, INC. (US) 2009-05-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131437-A1 DISUBSTITUTED UREAS AS KINASE INHIBITORS UCK2, ULK2, MAP3K1 MAPK14 133/4885MAPK13 103/4885MAPK12 214/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.